Barriers to Academic Centers for Hispanic Breast Cancer Population

Commentary
Video

The goal of creating the Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital is to establish a safe space for Hispanic patients, says Claudia Tellez, MD.

Several barriers may prevent Hispanic patients with breast cancer from receiving optimal care at academic institutions such as Northwestern Memorial Hospital, including transportation costs, concerns around language barriers, and navigating a large facility, according to Claudia Tellez, MD.

In an interview with CancerNetwork®, Tellez, a medical oncologist at Robert H. Lurie Comprehensive Cancer Center, Northwestern Memorial Hospital, discussed how her institution sought to create a better space for patients by launching the Hispanic Breast Cancer Clinic at Northwestern Hospital. All faculty working at the clinic are Spanish speakers who place an emphasis on determining patient concerns prior to coming to the clinic. This work is being done with the goal of ensuring that patients have a positive experience, Tellez says.

Transcript:

One of the biggest barriers to having patients come to a place like Northwestern has to do with the fact that patients are really scared to come to a big academic center not knowing if anyone is going to be able to speak their language. [It's] the thought of having an overwhelming diagnosis, going to a very scary place, being fearful of even paying for the parking, not really knowing how you're going to navigate the hallways, and not knowing if you're going to encounter anybody warm and courteous [who will] work with you.

One of the things that we wanted to do was to have the entire time in the clinic be a safe space for the patients. All the people in the clinic are Spanish speakers. We're trying to even communicate with the patients ahead of time to identify what their concerns and their worries are and to address some of the issues that might be a problem for that specific patient. That might be, again, a concern about parking, maybe a concern about paying for a ride; [we want] to try and address those issues to just facilitate and create a better experience for the patients.

Reference

Lurie Cancer Center Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital. Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Accessed November 6, 2023. https://bit.ly/45Vm0kx

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Related Content